Competitive intelligence on 
 small-molecule drugs and 
 the 90,000 global patents 
 covering them 

Start your free trial now

Plans and Pricing

DrugPatentWatch Ultimate Plan Preview

Profile for Tradename: ABILIFY

« Back to Dashboard
Abilify is a drug marketed by Otsuka and Otsuka Pharm Co Ltd and is included in five NDAs. It is available from fifteen suppliers. There are nineteen patents protecting this drug and three Paragraph IV challenges.

The generic ingredient in ABILIFY is aripiprazole. There are thirty-six drug master file entries for this compound. Fifteen suppliers are listed for this compound. There are eight tentative approvals for this compound. Additional details are available on the aripiprazole profile page.

Summary for Tradename: ABILIFY

Suppliers: see list15
2013 Sales:$6,460,215,000

Pharmacology for Tradename: ABILIFY

Clinical Trials for: ABILIFY

Aripiprazole and Topiramate on Free-Choice Alcohol Use
Status: Recruiting Condition: Alcohol Dependence

Intramuscular Depot Formulation of Aripiprazole as Maintenance Treatment in Patients With Schizophrenia
Status: Completed Condition: Schizophrenia

Efficacy of Aripiprazole Versus Placebo in the Reduction of Aggressive and Aberrant Behavior in Autistic Children
Status: Completed Condition: Autism

Abilify as an Adjunctive Treatment for Refractory Depression
Status: Completed Condition: Depressive Disorder, Major

A Multiple Dose Safety, Tolerability and Pharmacokinetics Study in Adult Patients With Schizophrenia Following Administration of Aripiprazole IM Depot
Status: Completed Condition: Schizophrenia

Aripiprazole (Abilify®) as an Adjunctive Treatment for Inadequate Response in Major Depressive Disorder
Status: Recruiting Condition: Major Depressive Disorder

Safety and Efficacy of Aripiprazole and Ziprasidone Among Schizophrenic Patients With Metabolic Syndrome
Status: Completed Condition: Schizophrenia

A Double-Blind, Placebo-Controlled Study of Aripiprazole Adjunctive to Antidepressant Therapy
Status: Completed Condition: Major Depressive Disorder

The Combination of Aripiprazole and Antidepressants in Psychotic Major Depression
Status: Completed Condition: Psychotic Depression

Aripiprazole Treatment for Methamphetamine Dependence Among High-risk Individuals
Status: Completed Condition: Substance Abuse; HIV Infections

Courtesy of
See more clinical trials for this drug
Applicant Tradename Generic Name Dosage NDA Approval Date Type RLD Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
TABLET;ORAL021436-004Nov 15, 2002RXNo<disabled><disabled>
TABLET;ORAL021436-002Nov 15, 2002RXNo<disabled><disabled>
TABLET;ORAL021436-006Nov 15, 2002RXNo8,642,760*PED<disabled>Y<disabled>
TABLET, ORALLY DISINTEGRATING;ORAL021729-002Jun 7, 2006RXYes8,759,350<disabled><disabled>
Otsuka Pharm Co Ltd
FOR SUSPENSION, EXTENDED RELEASE;INTRAMUSCULAR202971-002Feb 28, 2013RXYes7,807,680<disabled>Y<disabled>
This preview shows a limited data set
Subscribe for full access, or try a free trial

Export unavailable in trial.
Subscribe for complete access.

Paragraph IV activity for: ABILIFY

Drugname Dosage Strength RLD Submissiondate
aripiprazoleOral Solution1 mg/mLAbilify12/20/2007
aripiprazoleOrally Disintegrating Tablets10 mg, 15 mg, 20 mg and 30 mgAbilify11/15/2006
aripiprazoleTablets2 mg, 5 mg, 10 mg, 15 mg, 20 mg and 30 mgAbilify11/15/2006
« Back to Dashboard

DrugPatentWatch Archives

You are viewing the current data set
Select a link below to view the archives:

 2000   2001   2002   2003   2004   2005   2006   2007   2008   2009   2010   2011   2012   2013   2014  

For more information try a free trial or see the plan comparison

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors.

Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided information. There is no warranty that the information contained herein is error free. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

Copyright 2002-2015 thinkBiotech LLC
ISSN: 2162-2639

Preferred citation:

Friedman, Y. Location of pharmaceutical innovation: 2000–2009 Nature Reviews Drug Discovery 9, 835–836 (2010).

Connect with Social Media:

Follow DrugPatentWatch on Twitter
Connect with DrugPatentWatch on Linkedin
Drug Patents on LinkedIn